🇺🇸 Xianlinggubao in United States
3 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 28 March 2025 – 28 March 2026
- Total reports: 3
Most-reported reactions
- Blister — 1 report (33.33%)
- Chest Discomfort — 1 report (33.33%)
- Pain — 1 report (33.33%)
Other Other approved in United States
Frequently asked questions
Is Xianlinggubao approved in United States?
Xianlinggubao does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Xianlinggubao in United States?
Shanghai Jiao Tong University School of Medicine is the originator. The local marketing authorisation holder may differ — check the official source linked above.